<DOC>
	<DOCNO>NCT00720174</DOCNO>
	<brief_summary>This phase I trial study side effect best dose cixutumumab give together doxorubicin hydrochloride see well work treat patient unresectable , locally advanced , metastatic soft tissue sarcoma . Monoclonal antibody , cixutumumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , doxorubicin hydrochloride , work different way stop growth tumor cell , either kill cell stop divide . Giving monoclonal antibody cixutumumab together doxorubicin hydrochloride may kill tumor cell .</brief_summary>
	<brief_title>Cixutumumab Doxorubicin Hydrochloride Treating Patients With Unresectable , Locally Advanced , Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To collect safety data combination doxorubicin Cixitumumab determine combine acceptable toxicity full dos . SECONDARY OBJECTIVES : I . To assess confirm response rate ( CR + PR define RECIST ) patient locally advance metastatic soft tissue sarcoma treat combination doxorubicin Cixitumumab II . To assess 3 6 month progression free survival rate patient treat doxorubicin Cixitumumab . III . To assess progression free survival overall survival patient treat doxorubicin Cixitumumab . IV . To evaluate change leave ventricular ejection fraction assess MUGA scan 2 , 4 6 cycle therapy compare baseline . OUTLINE : This multicenter , dose-escalation study anti-IGF-1R recombinant monoclonal antibody cixutumumab . Patients receive cixutumumab intravenously ( IV ) 1 hour day 1 , 8 , 15 doxorubicin hydrochloride IV continuously 44-52 hour begin day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients stable respond disease may continue receive cixutumumab absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Embryonal</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<mesh_term>Chondrosarcoma</mesh_term>
	<mesh_term>Hemangiosarcoma</mesh_term>
	<mesh_term>Hemangiopericytoma</mesh_term>
	<mesh_term>Fibrosarcoma</mesh_term>
	<mesh_term>Mesenchymoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neurofibrosarcoma</mesh_term>
	<mesh_term>Dermatofibrosarcoma</mesh_term>
	<mesh_term>Histiocytoma , Malignant Fibrous</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Histologically cytologically confirm soft tissue sarcoma Unresectable disease Locally advance metastatic disease The following tumor type allow : Embryonal alveolar rhabdomyosarcoma Gastrointestinal stromal tumor Alveolar soft part sarcoma Clear cell sarcoma Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan No 1 prior therapy sarcoma No known brain metastasis ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % ANC ≥ 1,500/µL Platelet count ≥ 100,000/µL Leukocytes ≥ 3,000/µL Total bilirubin ≤ upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Creatinine ≤ 1.5 time ULN OR creatinine clearance ≥ 60 mL/min Fasting serum glucose &lt; 120 mg/dL OR ULN LVEF ≥ 50 % MUGA scan Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month last dose antiIGF1R recombinant monoclonal antibody IMCA12 No history allergic reaction attribute compound similar chemical biological composition antiIGF1R recombinant monoclonal antibody IMCA12 No poorly control diabetes mellitus Patients history diabetes mellitus eligible provide blood glucose within normal range stable dietary therapeutic regimen condition No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude compliance study requirement No concurrent investigational commercial agent therapy Recovered prior therapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) More 4 week since prior major surgery , hormonal therapy ( replacement ) , hormonal therapy No prior radiotherapy heart , mediastinum , chest wall No prior anthracycline therapy antiIGF1R therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>